collection
https://read.qxmd.com/read/30615156/myocardial-revascularization-guideline-based-therapy-today
#1
JOURNAL ARTICLE
Thomas F Lüscher
No abstract text is available yet for this article.
January 7, 2019: European Heart Journal
https://read.qxmd.com/read/30592446/chronic-obstructive-pulmonary-disease-copd
#2
JOURNAL ARTICLE
Suzanne C Lareau, Bonnie Fahy, Paula Meek, Angela Wang
No abstract text is available yet for this article.
January 1, 2019: American Journal of Respiratory and Critical Care Medicine
https://read.qxmd.com/read/30562267/peripheral-vestibular-disorders-an-update
#3
REVIEW
Michael Strupp, Marco Mandalà, Jose A López-Escámez
PURPOSE OF REVIEW: To provide an update on the most frequent peripheral vestibular disorders. RECENT FINDINGS: The on-going classification of vestibular disorders by the Bárány Society represents major progress. The diagnosis of bilateral vestibulopathy (BVP) requires quantitative testing of vestibular function. 'Acute unilateral peripheral vestibulopathy' (AUPVP) is now preferred over 'vestibular neuritis.' Menière's disease is a set of disorders with a significant genetic contribution...
February 2019: Current Opinion in Neurology
https://read.qxmd.com/read/30565021/practical-guidance-on-the-use-of-sacubitril-valsartan-for-heart-failure
#4
REVIEW
Andrew J Sauer, Robert Cole, Brian C Jensen, Jay Pal, Nakul Sharma, Amin Yehya, Justin Vader
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has been recommended in clinical practice guidelines to reduce morbidity and mortality in patients with chronic, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). This review provides an overview of ARNI therapy, proposes strategies to improve the implementation of sacubitril/valsartan in clinical practice, and provides clinicians with evidence-based, practical guidance on the use of sacubitril/valsartan in patients with HFrEF...
March 2019: Heart Failure Reviews
https://read.qxmd.com/read/30499630/how-i-investigate-eosinophilia
#5
REVIEW
Rebecca L Larsen, Natasha M Savage
Eosinophilia is typically secondary, that is, reactive, in nature and is associated with a wide variety of neoplastic and non-neoplastic disorders. Clonal eosinophilia is also seen in a wide variety of hematopoietic neoplasms, and sub-classification can be diagnostically challenging. A proper evaluation of persistent eosinophilia involves correlation of clinical history, laboratory data, cellular morphology, and ancillary testing. Knowledge of appropriate ancillary testing is necessary for a timely diagnosis...
April 2019: International Journal of Laboratory Hematology
https://read.qxmd.com/read/30540968/crystalloids-vs-colloids-for-fluid-resuscitation-in-the-intensive-care-unit-a-systematic-review-and-meta-analysis
#6
COMPARATIVE STUDY
Greg S Martin, Paul Bassett
PURPOSE: Guidelines recommend crystalloids for fluid resuscitation in sepsis/shock and switching to albumin in cases where crystalloids are insufficient. We evaluated hemodynamic response to crystalloids/colloids in critically ill adults. MATERIALS AND METHODS: The primary research question was: "Are crystalloids sufficient for volume replacement in severe indications (intensive care unit [ICU]/critical illness)?" Randomized, controlled trials (RCTs) were identified using PubMed and EMBASE, and screened against predefined inclusion/exclusion criteria...
April 2019: Journal of Critical Care
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.